Lévy E, Los F, Chevalier H, Lévy P
LEGOS, Université Paris IX Dauphine, Paris, France.
Angiology. 2001 Mar;52(3):195-9. doi: 10.1177/000331970105200306.
A recent (1999) Sofres survey of representative samples of the adult French population aged 15 and over showed that almost half this population suffered from lower limb venous complaints and that 43% of them were untreated. Of those treated, 24.2% received venotropics, including 21.5% by prescription, while 6.0% practiced self-medication. Venous disease sufferers form a relatively underprivileged sector of the population in terms not only of age, income, work and living conditions, but also of general health and medical history. Despite its clinical efficacy and potential social utility, venotropic treatment is possible only if backed by adequate state health insurance coverage supplemented by mutual and private insurance schemes. Any restriction to such coverage will only decrease access to prescription venotropics.
近期（1999年）索福瑞公司对15岁及以上法国成年人口代表性样本进行的一项调查显示，近半数该人群患有下肢静脉疾病，其中43%未接受治疗。在接受治疗的人群中，24.2%使用了静脉活性药物，其中21.5%是通过处方用药，而6.0%是自行用药。静脉疾病患者不仅在年龄、收入、工作和生活条件方面，而且在总体健康状况和病史方面，都构成了相对弱势的人群。尽管静脉活性治疗具有临床疗效和潜在的社会效用，但只有在国家医疗保险提供足够保障，并由互助保险和私人保险计划予以补充的情况下，才有可能进行。对这种保险覆盖范围的任何限制都只会减少获得处方静脉活性药物的机会。
